| Name | Title | Contact Details |
|---|
In a complex healthcare world, Medline strives to help our customers achieve both clinical and financial success. We do that through a personalized approach to listen and better understand our customers` needs in an environment that tirelessly demands lower costs and better outcomes. We are both a manufacturer and distributor with 1,200 direct sales reps who are dedicated points of contact for customers across the continuum of care. Because of our capabilities and engagement with other clinical and industry thought leaders, we deliver the most robust product portfolio and patient-care solutions to help healthcare providers perform at their very best. Our responsiveness and commitment to advancing the health of healthcare is evident in our actions every day. This is who we are. This is why customers choose us as their trusted business partner.
We are Nuwellis, (Nasdaq: NUWE) formerly CHF Solutions. Our solutions go beyond chronic heart failure, so we`ve rebranded to reflect our therapeutic focus areas: heart failure, critical care, and pediatric fluid imbalance. We are a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. Our Aquadex SmartFlow® System gently removes fluid from adult and pediatric patients weighing 20 kg or more. Nuwellis consists of a purpose-driven team that puts patients and their providers at the center of everything we do. This is the new well. And for those whose lives and life`s work are transformed by our fluid management technologies, the new well is everything. Nuwellis is headquartered in Minneapolis, Minn., with a wholly-owned subsidiary in Ireland. The Company has been listed on the Nasdaq Capital Market since February 2012, previously branded as CHF Solutions.
MY01 is a state-of-the-art medical device geared towards aiding in the detection of Compartment Syndrome (CS); a limb-threatening muscle condition that occurs within 48 hours following trauma. Currently, ACS is diagnosed based on subjective and unreliable outcomes like pain (known as 6 P`s), which when present cannot confirm the diagnosis in time for effective intervention. This leads to increased complications (muscle necrosis/amputation) and costs the US healthcare system more than $2.25 B annually. MY01 is capitalizing on a proven correlation between sustained increase in Intramuscular pressures and ACS for objective, early diagnosis. MY01 operationalizes muscular pressure monitoring into a simple, accurate single-use device. MY01. The simple solution to a dangerous problem.
iTeknik Holding Corporation is a Commerce Township, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ossio is an orthopedic medical device company founded in Israel in 2014 with the vision to completely transform the orthopedic experience for physicians, patients, and payors. Ossio`s mission is to replace metal implants as the standard of care in the $10B+ orthopedic fixation market (screws, pins, plates) with an intelligent bone regeneration technology.